Goodwill and Intangible Assets, net	12 Months Ended
Dec. 31, 2020
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, net	Note 6. Goodwill and Intangible Assets, net Goodwill During the year ended December 31, 2020, the Company did not dispose of, impair or recognize additional goodwill. Intangible Assets, net Intangible assets, net, which include a license for the right to commercialize the INTERCEPT Blood System in Asia, were subject to ratable amortization over the original estimated useful life of ten years. Intangible assets were fully amortized as of December 31, 2020. Accumulated amortization of intangible assets as of December 31, 2020, and December 31, 2019, was $2.0 million and $1.9 million, respectively.

Goodwill and Intangible Assets, net

12 Months Ended

Dec. 31, 2020

Goodwill And Intangible Assets Disclosure [Abstract]

Note 6. Goodwill and Intangible Assets, net

Goodwill

During the year ended December 31, 2020, the Company did not dispose of, impair or recognize additional goodwill.

Intangible Assets, net

Intangible assets, net, which include a license for the right to commercialize the INTERCEPT Blood System in Asia, were subject to ratable amortization over the original estimated useful life of ten years. Intangible assets were fully amortized as of December 31, 2020. Accumulated amortization of intangible assets as of December 31, 2020, and December 31, 2019, was $2.0 million and $1.9 million, respectively.